REPLY
13.12.2022 09:31:35 CET | Business Wire | Press release
POLIMI Graduate School of Management, Politecnico di Milano’s business school, and Reply, a company that has made innovation and technological specialisation its flagship, join forces to create a training path for excellence, which is aimed at preparing the professionals the industry needs to face future challenges.
Enrolment is now open for POLIMI Graduate School of Management Master's in "Digital Finance", which aims to offer highly qualified students a professional specialisation in financial services (fintech and insurtech) with a practical and experiential approach to innovation and new technologies such as: Artificial Intelligence, Machine Learning and Cloud.
The postgraduate course will start in April 2023 and will last 18 months. The Master’s includes a series of introductory courses on Business Management and Financial Services followed by a specialisation course aimed at training technical experts in the latest digital technologies (e.g. Cloud, AI, ML, etc.) applicable to the Financial Services market.
The lessons will be held online based on an executive model (lesson delivery will be on Fridays and Saturdays, for approximately 2 weekends per month) and the professors will be a mix of POLIMI Graduate School of Management academics and Reply specialists to combine theoretical lessons, workshops, hackathons and projects. The course will also include face-to-face meetings (2 or 3 over the course of the programme) at Politecnico di Milano laboratories or Reply offices. In the final stage of the course, students will carry out a 6-month work project at Reply, where they will put into practice the knowledge acquired in the classroom working in groups on live projects. The entire course is in English and open to international candidates.
The Master’s, at its first edition, is aimed at students with a Bachelor's or Master's degree in Computer Science, Computer Engineering, Cybersecurity, Automation Engineering, Electronics Engineering and Telecommunication Engineering which must be achieved by 31 March 2023 for three-year degrees, or by 31 July 2023 for Master's degrees.
Reply has committed to hire all candidates who are successful in their application and will bear the cost of the Master’s enrolment fees of those students who accept the job offer.
There are 50 places available and applications can be sent via the official website: master.reply.com. Applications will be accepted until all available places are filled, or until the deadline of March 13 2023.
More information available at master.reply.com.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
POLIMI GRADUATE SCHOOL OF MANAGEMENT
At POLIMI Graduate School of Management we create meaningful paths for future business leaders and the businesses they will lead, guided by the over-arching belief that we have a crucial role to play in shaping a better world for all. Based in Milan, Italy’s main business centre, our school was created over 40 years ago as MIP Politecnico di Milano and today it is a not-for-profit Consortia Limited Company composed of the University and a group of leading Italian and multinational companies. We offer more than 40 masters degrees, including MBA and EMBA, and a catalogue of over 200 open programmes, along with customised training for companies. We continue to innovate and our digital learning systems allow us to seamlessly integrate personalized and continuous learning experiences into our programmes and have placed us amongst the top-ranked Online MBA rankings globally. As part of the School of Management of Politecnico di Milano, we are among the few “Triple Crown” accredited schools across the world. With over 15,000 alumni and 3,000 students every year we are an innovative and entrepreneurial community made up of diverse people and partners. We see the power of relationships as a constant source of enrichment, innovation and inspiration, personal and professional. At POLIMI Graduate School of Management we take sustainability seriously and continue to work towards a better, more conscious, more equitable and more inclusive future. In 2020 we were the first European Business School to become a B Corp certified business. www.gsom.polimi.it/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005091/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom